$91.54
5.54% yesterday
Nasdaq, Nov 20, 10:00 pm CET
ISIN
US7207951036
Symbol
PVLA

Pieris Pharmaceuticals, Inc. Stock price

$91.54
+13.87 17.86% 1M
+68.31 294.06% 6M
+79.54 662.83% YTD
+75.53 471.77% 1Y
+14.92 19.48% 3Y
-130.86 58.84% 5Y
-83.66 47.75% 10Y
-128.46 58.39% 20Y
Nasdaq, Closing price Thu, Nov 20 2025
-5.37 5.54%
ISIN
US7207951036
Symbol
PVLA
Industry

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$1.1b
Net debt
positive
Cash
$70.4m
Shares outstanding
11.1m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
24.0
Financial Health
Equity Ratio
71.0%
Return on Equity
-27.2%
ROCE
-
ROIC
-
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | $-37.3m
EBIT
- | $-37.3m
Net Income
- | $-36.9m
Free Cash Flow
$-14.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -166.7%
Net Income
- | -117.0%
Free Cash Flow
61.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-1.3
Short interest
8.3%
Employees
-
Rev per Employee
-
Show more

Is Pieris Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Pieris Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Pieris Pharmaceuticals, Inc. forecast:

Buy
95%
Hold
5%

Financial data from Pieris Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.65 3.65
78% 78%
-
- Research and Development Expense - -
-
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -15 -15
21% 21%
-
Net Profit -22 -22
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Pieris Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Pieris Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
Palvella's recently expanded rare disease pipeline now comprises QTORIN™-derived product candidates advancing in four serious, rare skin diseases that currently have no FDA-approved therapies
Neutral
GlobeNewsWire
14 days ago
WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella or “the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen,...
Neutral
GlobeNewsWire
16 days ago
DSAP is a premalignant, progressive disease characterized by numerous expanding lesions which significantly impact quality-of-life; no FDA-approved therapies exist for the estimated more than 50,000 diagnosed U.S. patients
More Pieris Pharmaceuticals, Inc. News

Company Profile

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Head office United States
CEO Wesley Kaupinen
Founded 2001
Website palvellatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today